Hepatic loss of miR-122 predisposes mice to hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine exposure

Am J Pathol. 2013 Dec;183(6):1719-1730. doi: 10.1016/j.ajpath.2013.08.004. Epub 2013 Oct 8.

Abstract

Loss of miR-122 causes chronic steatohepatitis and spontaneous hepatocellular carcinoma. However, the consequence of miR-122 deficiency on genotoxic stress-induced liver pathogenesis is poorly understood. Here, we investigated the impact of miR-122 depletion on liver pathobiology by treating liver-specific miR-122 knockout (LKO) mice with the hepatocarcinogen diethylnitrosamine (DEN). At 25 weeks post-DEN injection, all LKO mice developed CK-19-positive hepatobiliary cysts, which correlated with DEN-induced transcriptional activation of Cdc25a mediated through E2f1. Additionally, LKO livers were more fibrotic and vascular, and developed larger microscopic tumors, possibly due to elevation of the Axl oncogene, a receptor tyrosine kinase as a novel target of miR-122, and several protumorigenic miR-122 targets. At 35 weeks following DEN exposure, LKO mice exhibited a higher incidence of macroscopic liver tumors (71%) and cysts (86%) compared to a 21.4% and 0% incidence of tumors and cysts, respectively, in control mice. The tumors in LKO mice were bigger (ninefold, P = 0.015) and predominantly hepatocellular carcinoma, whereas control mice mostly developed hepatocellular adenoma. DEN treatment also reduced survival of LKO mice compared to control mice (P = 0.03). Interestingly, induction of oxidative stress and proinflammatory cytokines in LKO liver shortly after DEN exposure indicates predisposition of a pro-tumorigenic microenvironment. Collectively, miR-122 depletion facilitates cystogenesis and hepatocarcinogenesis in mice on DEN challenge by up-regulating several genes involved in proliferation, growth factor signaling, neovascularization, and metastasis.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Alkylating Agents / adverse effects*
  • Alkylating Agents / pharmacology
  • Animals
  • Axl Receptor Tyrosine Kinase
  • Carcinoma, Hepatocellular* / chemically induced
  • Carcinoma, Hepatocellular* / genetics
  • Carcinoma, Hepatocellular* / metabolism
  • Carcinoma, Hepatocellular* / pathology
  • Cell Proliferation / drug effects
  • Cysts* / chemically induced
  • Cysts* / genetics
  • Cysts* / metabolism
  • Cysts* / pathology
  • Cytokines / biosynthesis
  • Cytokines / genetics
  • Diethylnitrosamine / adverse effects*
  • Diethylnitrosamine / pharmacology
  • E2F1 Transcription Factor / biosynthesis
  • E2F1 Transcription Factor / genetics
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Expression Regulation, Neoplastic / genetics
  • Liver Neoplasms* / chemically induced
  • Liver Neoplasms* / genetics
  • Liver Neoplasms* / metabolism
  • Liver Neoplasms* / pathology
  • Mice
  • Mice, Knockout
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Neoplasm Metastasis
  • Proto-Oncogene Proteins / biosynthesis
  • Proto-Oncogene Proteins / genetics
  • Receptor Protein-Tyrosine Kinases / biosynthesis
  • Receptor Protein-Tyrosine Kinases / genetics
  • Signal Transduction / drug effects
  • Signal Transduction / genetics
  • cdc25 Phosphatases / biosynthesis
  • cdc25 Phosphatases / genetics

Substances

  • Alkylating Agents
  • Cytokines
  • E2F1 Transcription Factor
  • E2f1 protein, mouse
  • MicroRNAs
  • Mirn122 microRNA, mouse
  • Proto-Oncogene Proteins
  • Diethylnitrosamine
  • Receptor Protein-Tyrosine Kinases
  • Cdc25a protein, mouse
  • cdc25 Phosphatases
  • Axl Receptor Tyrosine Kinase
  • AXL receptor tyrosine kinase, mouse